Primary Peritoneal Cancer

Also known as: Peritoneal Carcinoma / Peritoneal cancer / Malignant peritoneal neoplasm / Malignant neoplasm of peritoneum, unspecified / Malignant peritoneal neoplasm NOS

DrugDrug NameDrug Description
DB11793NiraparibNiraparib is an orally active PARP inhibitor developed by Tesaro to treat ovarian cancer. FDA approval on March 2017.
DrugDrug NamePhaseStatusCount
DB00041Aldesleukin1Not Yet Recruiting1
DB00112Bevacizumab1Active Not Recruiting4
DB00112Bevacizumab1Completed1
DB00112Bevacizumab1Recruiting1
DB00188Bortezomib1Completed1
DB00958Carboplatin1Active Not Recruiting1
DB00958Carboplatin1Completed4
DB00958Carboplatin1Not Yet Recruiting1
DB00958Carboplatin1Recruiting2
DB00958Carboplatin1Unknown Status1
DB00493Cefotaxime1Not Yet Recruiting1
DB00515Cisplatin1Active Not Recruiting1
DB00531Cyclophosphamide1Not Yet Recruiting1
DB00531Cyclophosphamide1Recruiting1
DB01262Decitabine1Not Yet Recruiting1
DB00997Doxorubicin1Recruiting1
DB12489Mirvetuximab Soravtansine1Recruiting1
DB09035Nivolumab1Recruiting2
DB09074Olaparib1Active Not Recruiting1
DB09074Olaparib1Completed1
DB01229Paclitaxel1Active Not Recruiting3
DB01229Paclitaxel1Completed1
DB01229Paclitaxel1Not Yet Recruiting1
DB01229Paclitaxel1Recruiting1
DB09037Pembrolizumab1Recruiting1
DB12257Platinum1Unknown Status1
DB11730Ribociclib1Not Yet Recruiting1
DB12376Ricolinostat1Active Not Recruiting1
DB00853Temozolomide1Completed1
DB07232Veliparib1Completed1
DB00112Bevacizumab1 / 2Withdrawn1
DB00958Carboplatin1 / 2Active Not Recruiting1
DB00531Cyclophosphamide1 / 2Withdrawn1
DB00997Doxorubicin1 / 2Terminated1
DB12047Ganetespib1 / 2Suspended1
DB00441Gemcitabine1 / 2Active Not Recruiting1
DB01229Paclitaxel1 / 2Suspended1
DB06589Pazopanib1 / 2Terminated1
DB00642Pemetrexed1 / 2Completed1
DB11787Ralimetinib1 / 2Active Not Recruiting1
DB10286Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria crm197 protein conjugate antigen1 / 2Active Not Recruiting1
DB11760Talazoparib1 / 2Recruiting1
DB01217Anastrozole2Completed1
DB00112Bevacizumab2Completed2
DB00112Bevacizumab2Recruiting2
DB00112Bevacizumab2Terminated3
DB00958Carboplatin2Completed1
DB00958Carboplatin2Recruiting2
DB00958Carboplatin2Terminated2
DB00958Carboplatin2Unknown Status1
DB00515Cisplatin2Completed1
DB00515Cisplatin2Not Yet Recruiting1
DB00515Cisplatin2Terminated1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Terminated1
DB00091Cyclosporine2Completed1
DB00997Doxorubicin2Active Not Recruiting1
DB00530Erlotinib2Completed1
DB01073Fludarabine2Completed1
DB00317Gefitinib2Completed1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Terminated3
DB00441Gemcitabine2Unknown Status1
DB00619Imatinib2Completed1
DB00724Imiquimod2Active Not Recruiting1
DB04845Ixabepilone2Recruiting1
DB00959Methylprednisolone2Completed1
DB12303Motolimod2Active Not Recruiting1
DB00526Oxaliplatin2Terminated2
DB01229Paclitaxel2Active Not Recruiting1
DB01229Paclitaxel2Completed3
DB01229Paclitaxel2Not Yet Recruiting1
DB01229Paclitaxel2Recruiting1
DB01229Paclitaxel2Terminated1
DB01229Paclitaxel2Unknown Status1
DB01269Panitumumab2Terminated1
DB09037Pembrolizumab2Recruiting1
DB00642Pemetrexed2Completed1
DB08896Regorafenib2Terminated1
DB00020Sargramostim2Active Not Recruiting1
DB00020Sargramostim2Completed1
DB00398Sorafenib2Completed1
DB11941Tasisulam2Completed1
DB01030Topotecan2Completed1
DB12056Trebananib2Active Not Recruiting1
DB07232Veliparib2Terminated1
DB00361Vinorelbine2Completed1
DB01229Paclitaxel2 / 3Completed1
DB11805Saracatinib2 / 3Completed1
DB06274Alvimopan3Completed1
DB00958Carboplatin3Unknown Status1
DB00033Interferon gamma-1b3Terminated1
DB01229Paclitaxel3Completed2
DB01229Paclitaxel3Unknown Status1
DB12056Trebananib3Completed1
DB00958CarboplatinNot AvailableCompleted1
DB01229PaclitaxelNot AvailableCompleted1